KEYNOTE-975
Regimen
- Experimental
- pembrolizumab + definitive chemoradiotherapy
- Control
- placebo + definitive chemoradiotherapy
Population
Locally advanced unresectable esophageal or GEJ cancer, first-line (design paper; trial ongoing)
Key finding
Design paper only; OS/EFS dual primary endpoints. Enrollment completed; results awaited as of early 2026.
Source: PMID 33533655